カテゴリ： GlobalData, スウェーデン, 企業調査

Swedish Orphan Biovitrum AB (SOBI)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Swedish Orphan Biovitrum AB (SOBI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10048
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：80
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スウェーデン
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Swedish Orphan Biovitrum AB (Sobi), formerly Biovitrum AB, is an integrated biopharmaceutical company that focuses on the development of products for the treatment of rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on haemophilia, inflammation and genetic and metabolic diseases. The company’s products include Alprolix, Ammonaps, Elocta, Kepivance, Kineret and Orfadin. Sobi also manufactures and markets specialty and rare disease products for partner companies. It has operational presence in Europe, the Middle East and North Africa. Sobi is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB (SOBI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deal Details 14
Private Equity 14
Swedish Orphan Biovitrum Plans to Sell Partner Products Business 14
Partnerships 15
Baylor Research Enters into Licensing Agreement with Swedish Orphan Biovitrum 15
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 16
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 17
ModiQuest Research Enters into Agreement with Swedish Orphan Biovitrum 18
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 19
Biogen’s Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 20
Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 21
Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 22
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 23
Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 24
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 25
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 29
Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 30
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 31
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 32
Licensing Agreements 33
Swedish Orphan Biovitrum Enters into Licensing Agreement with Novimmune 33
Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 34
Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 35
TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 36
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Only for Children Pharma For Neonatology Treatment 37
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 38
Debt Offering 40
Swedish Orphan Biovitrum Announces Private Placement Of Senior Bonds Due 2017 For US$86 Million 40
Swedish Orphan Biovitrum AB – Key Competitors 41
Swedish Orphan Biovitrum AB – Key Employees 42
Swedish Orphan Biovitrum AB – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 45
Financial Announcements 45
Oct 31, 2018: Sobi publishes the report for the third quarter 2018 45
Jul 18, 2018: Sobi publishes the report for the second quarter 2018 46
Apr 26, 2018: Sobi publishes the report for the first quarter 2018 47
Feb 22, 2018: Sobi publishes its report for the fourth quarter and full-year 2017 48
Oct 25, 2017: Sobi publishes its report for the third quarter 2017 49
Jul 19, 2017: Sobi publishes its report for the second quarter 2017 50
Apr 28, 2017: Sobi publishes its report for the first quarter 2017 51
Feb 16, 2017: Sobi publishes its report for the fourth quarter and full year 2016 52
Corporate Communications 53
Aug 22, 2018: Swedish Orphan Biovitrum names Anne Marie de Jonge Schuermans as head of technical operations 53
Feb 26, 2018: Swedish Orphan Biovitrum Appoints Henrik Stenqvist As New Chief Financial Officer 54
Oct 06, 2017: Norbert Oppitz joins Sobi as new Senior Vice President, Specialty Care 55
Jun 07, 2017: Chief Operating Officer Alan Raffensperger to leave Sobi 56
May 04, 2017: Guido Oelkers Appointed President and CEO at Sobi 57
Apr 07, 2017: Theresa Heggie resigns from the Board of Directors and will not be proposed for re-election at Sobi’s annual general meeting 2017 58
Jan 09, 2017: CEO Geoffrey McDonough to leave Swedish Orphan Biovitrum 59
Product News 60
12/13/2017: Sobi Launches Orfadin (nitisinone) Ambassador Program to Support Patients and Caregivers Living with Hereditary Tyrosinemia Type 1 (HT-1) 60
11/27/2017: Sobi Receives Approval From Health Canada for Orfadin (nitisinone) Oral Suspension for the Treatment of HT-1 61
09/05/2017: Sobi Receives Approval From the FDA for Once-Daily Dosing Frequency of Orfadin (nitisinone) for the Treatment of HT-1 62
05/28/2018: FDA Accepts emapalumab Biologics License Application with Priority Review 63
05/17/2017: Orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1 64
04/17/2018: Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin (nitisinone) for the Treatment of HT-1 65
03/27/2017: Novimmune opens a Branch Office in Basel 66
03/07/2017: FDA approves in-use storage at room temperature for Orfadin capsules 67
02/27/2018: Sobi’s Orfadin (nitisinone) Receives Positive Reimbursement Recommendation for the Treatment of HT-1 from CADTH Canadian Drug Expert Committee 68
02/02/2017: Sobi obtains approval from the European Commission for new dosing frequency of Orfadin 69
01/04/2017: Health Canada Approves Orfadin Capsules for Treatment of Hereditary Tyrosinaemia Type-1 (HT-1) 70
Product Approvals 71
Mar 29, 2018: Novimmune submits Biologics License Application in the US for its lead drug emapalumab 71
Jan 23, 2018: FDA accepts investigational new drug application and grants Fast Track status for SOBI003 for the treatment of MPS IIIA 72
Sep 05, 2017: Novimmune Receives Rare Pediatric Disease Designation from the FDA for its Lead Drug emapalumab 73
Jul 05, 2017: FDA grants SOBI003 Orphan Drug Designation for the treatment of MPS IIIA 74
Other Significant Developments 75
May 31, 2018: Sobi discloses payments to healthcare professionals and healthcare organisations to increase transparency 75
Apr 17, 2018: Sobi publishes 2017 Annual and Sustainability Report 76
Feb 28, 2018: Sobi Launches Enhanced Corporate Sustainability Initiative 77
Jun 05, 2017: Sobi Keeps the Partner Products Business Area as an Integral Part of the Company 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80

List of Tables
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Swedish Orphan Biovitrum AB, Deals By Therapy Area, 2012 to YTD 2018 9
Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Swedish Orphan Biovitrum Plans to Sell Partner Products Business 14
Baylor Research Enters into Licensing Agreement with Swedish Orphan Biovitrum 15
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 16
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 17
ModiQuest Research Enters into Agreement with Swedish Orphan Biovitrum 18
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 19
Biogen’s Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 20
Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 21
Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 22
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 23
Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 24
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 25
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 29
Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 30
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 31
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 32
Swedish Orphan Biovitrum Enters into Licensing Agreement with Novimmune 33
Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 34
Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 35
TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 36
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Only for Children Pharma For Neonatology Treatment 37
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 38
Swedish Orphan Biovitrum Announces Private Placement Of Senior Bonds Due 2017 For US$86 Million 40
Swedish Orphan Biovitrum AB, Key Competitors 41
Swedish Orphan Biovitrum AB, Key Employees 42
Swedish Orphan Biovitrum AB, Subsidiaries 43

List of Figures
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Swedish Orphan Biovitrum AB (SOBI)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • EP Energy Corp (EPE)：石油・ガス：M&Aディール及び事業提携情報
    Summary EP Energy Corp (EP Energy) is an oil and gas exploration and production company that offers acquisition and development of unconventional onshore oil and natural gas properties in the US. The company operates Altamont program, Eagle Ford program and Wolfcamp program. Its Eagle Ford program i …
  • Telecom Egypt Company：企業の戦略・SWOT・財務分析
    Telecom Egypt Company - Strategy, SWOT and Corporate Finance Report Summary Telecom Egypt Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Midatech Pharma Plc (MTPH)-医療機器分野：企業M&A・提携分析
    Summary Midatech Pharma Plc (Midatech) is a pharmaceutical company that develops and commercialize oncology and other therapeutic products. The company’s products include gelclair, oravig, soltamox, zuplenz, ferralet 90 and aquoral. It conducts research and development programs in areas of oncology, …
  • Raymond Ltd (RAYMOND)：企業の財務・戦略的SWOT分析
    Raymond Ltd (RAYMOND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Bioceros BV-製薬・医療分野：企業M&A・提携分析
    Summary Bioceros BV (Bioceros) is a biopharmaceutical company which provides services related to preclinical development of monoclonal antibodies. The company offers GMP-ready protein producing cell lines. The company provides services which include monoclonal antibody generation, cell line and proc …
  • Astute Medical Inc-医療機器分野：企業M&A・提携分析
    Summary Astute Medical Inc (Astute Medical) is a healthcare service provider that provides diagnostic products. The company offers biomarker products such as nephro check test and astute meter. Its products are used in the field of identifying and validating biomarkers of acute kidney injury through …
  • Vaisala oyj (VAIAS)：企業の財務・戦略的SWOT分析
    Summary Vaisala oyj (Vaisala) is a manufacturer of industrial and environmental measurement products. Its products include automatic weather stations and sensors, aviation weather systems, wireless temperature and humidity data loggers, indoor monitoring systems, weather radar products, rail weather …
  • IPCA Laboratories Ltd (IPCALAB)：企業の財務・戦略的SWOT分析
    Summary IPCA Laboratories Ltd (IPCA) is a pharmaceutical company which manufactures and markets active pharmaceutical ingredients, generics and formulations for various therapeutic areas. The company’s active pharmaceutical ingredients include anti-hypertensive, anti-malarial, diuretic and anthelmin …
  • Sabre Corporation：企業の戦略・SWOT・財務情報
    Sabre Corporation - Strategy, SWOT and Corporate Finance Report Summary Sabre Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Dentsu Inc (4324)：企業の財務・戦略的SWOT分析
    Dentsu Inc (4324) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bank of Montreal：企業のM&A・事業提携・投資動向
    Bank of Montreal - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Montreal Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Novozymes AS (NZYM B)：企業の財務・戦略的SWOT分析
    Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Spark New Zealand Ltd：企業の戦略・SWOT・財務分析
    Spark New Zealand Ltd - Strategy, SWOT and Corporate Finance Report Summary Spark New Zealand Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • CASIO COMPUTER CO., LTD.：企業の戦略・SWOT・財務情報
    CASIO COMPUTER CO., LTD. - Strategy, SWOT and Corporate Finance Report Summary CASIO COMPUTER CO., LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Biosceptre International Ltd：企業の製品パイプライン分析2018
    Summary Biosceptre International Ltd (Biosceptre) is a biotechnology company that develops antibody technologies for applications in the diagnosis and treatment of cancer. The company develops imaging technologies to detect and monitor cancer. Its diagnostic products are used for the detection of va …
  • Menssana Research Inc：企業の製品パイプライン分析2018
    Summary Menssana Research Inc (Menssana) is a medical device development company that develops breath test systems. The company offers BreathLink a cloud application that concentrates, collects, and analyzes organic compounds in human breath. It also provides Breathscanner a mobile point of care sys …
  • Theravasc Inc-製薬・医療分野：企業M&A・提携分析
    Summary Theravasc Inc (Theravasc) is a healthcare services provider that develops treatments for various chronic medical diseases using oral formulation of sodium nitrite. The company’s product TV1001SR is a coated oral formulation of sodium nitrite for the treatment of peripheral artery diseases an …
  • Wave 80 Biosciences Inc：企業の製品パイプライン分析2018
    Summary Wave 80 Biosciences Inc (Wave 80) is a medical device company that develops molecular diagnostic instruments and consumables. The company develops molecular diagnostics instruments for chlamydia, respiratory illness, cancers, autoimmune diseases, hepatitis B, hepatitis C, HIV/AIDS and other …
  • Nissin Foods Holdings Co Ltd.：企業の戦略・SWOT・財務分析
    Nissin Foods Holdings Co Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nissin Foods Holdings Co Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • China National Offshore Oil Corp：企業の戦略的SWOT分析
    China National Offshore Oil Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆